Sanofi acquires therapeutic acne vaccine
Sanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology.
Privately-owned Origrimm, based in Vienna, develops a vaccine-based immunotherapy against acne. ORI-001 is potentially the first-in-class vaccine candidate in acne vulgaris, a common chronic skin disease currently without adequate treatment available. The candidate is based on recombinant proteins, which entered preliminary clinical studies in Q3 2021. With the deal, Sanofi aims to complement its mRNA vaccine research platform.
The acquisition of Origimm further broadens our vaccines R&D pipeline with a first vaccine candidate against acne, a high medical need for millions of teenagers and adults, says Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur. Welcoming Origimm within Sanofi expands our area of expertise by bringing extensive know-how in the field of skin microbiome and skin immunology. We look forward to unlocking the full potential of this candidate.
The partners stayed mum on the financial details.
Biocytogen Co Ltd
Draupnir Bio ApS